rs141314684
Variant summary
Our verdict is Benign. Variant got -11 ACMG points: 2P and 13B. PM1BP4_StrongBP6BS1BS2
The NM_001232.4(CASQ2):c.928G>A(p.Asp310Asn) variant causes a missense change. The variant allele was found at a frequency of 0.000513 in 1,611,510 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. D310D) has been classified as Likely benign.
Frequency
Consequence
NM_001232.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CASQ2 | NM_001232.4 | c.928G>A | p.Asp310Asn | missense_variant | 9/11 | ENST00000261448.6 | NP_001223.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASQ2 | ENST00000261448.6 | c.928G>A | p.Asp310Asn | missense_variant | 9/11 | 1 | NM_001232.4 | ENSP00000261448.5 | ||
CASQ2 | ENST00000488931.2 | n.*300G>A | non_coding_transcript_exon_variant | 11/13 | 3 | ENSP00000518226.1 | ||||
CASQ2 | ENST00000488931.2 | n.*300G>A | 3_prime_UTR_variant | 11/13 | 3 | ENSP00000518226.1 |
Frequencies
GnomAD3 genomes AF: 0.000420 AC: 64AN: 152234Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000700 AC: 176AN: 251352Hom.: 0 AF XY: 0.000766 AC XY: 104AN XY: 135842
GnomAD4 exome AF: 0.000523 AC: 763AN: 1459158Hom.: 3 Cov.: 30 AF XY: 0.000551 AC XY: 400AN XY: 726106
GnomAD4 genome AF: 0.000420 AC: 64AN: 152352Hom.: 0 Cov.: 32 AF XY: 0.000443 AC XY: 33AN XY: 74506
ClinVar
Submissions by phenotype
not specified Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 29, 2015 | The p.Asp310Asn variant in CASQ2 has been identified by our laboratory in 1 teen ager with DCM and in 1 teenager with DCM and LVNC. In addition, this variant has been identified in 0.1% (18/16512) of South Asian chromosomes and 0.08% (55/666 77) European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac. broadinstitute.org; dbSNP rs141314684). Computational prediction tools and conse rvation analysis do not provide strong support for or against an impact to the p rotein. In summary, the clinical significance of the p.Asp310Asn variant is unce rtain. - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 06, 2022 | Variant summary: CASQ2 c.928G>A (p.Asp310Asn) results in a conservative amino acid change located in the Calsequestrin, C-terminal TRX-fold domain (IPR041860) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00063 in 282758 control chromosomes, predominantly at a frequency of 0.0046 within the Ashkenazi Jewish subpopulation in the gnomAD database. The observed variant frequency within Ashkenazi Jewish control individuals in the gnomAD database is approximately 3 fold of the estimated maximal expected allele frequency for a pathogenic variant in CASQ2 causing Catecholaminergic Polymorphic Ventricular Tachycardia phenotype (0.0016), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Ashkenazi Jewish origin. c.928G>A has been reported in the literature in individuals affected with Brugada syndrome, Sudden Death, QT syndrome and unknown arrhythmia as well as asymptomatic individuals (Behr_2015, Sanchez_2016, Celestino-Soper_2017, Landstrom_2017, Ng_2020). These reports do not provide unequivocal conclusions about association of the variant with Catecholaminergic Polymorphic Ventricular Tachycardia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=4), likely benign (n=1) and benign (n=1). Based on the evidence outlined above, the variant was classified as likely benign. - |
Catecholaminergic polymorphic ventricular tachycardia 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Mar 08, 2018 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 19, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25691538, 28404607, 25351510, 30847666, 35932045, 36291626, 28361054, 32693635, 27930701) - |
Cardiomyopathy Benign:1
Benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Mar 06, 2018 | - - |
Catecholaminergic polymorphic ventricular tachycardia 1 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2023 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at